Platform Access Over Asset Buys, and Diagnostics AI as Oncology’s New Moat

Platform Access and Regional Rights Are Replacing One-Off Asset Buys

Large pharma is using external deals to refill pipelines through platform access, regional carve-outs, and staged risk sharing rather than waiting for later-stage assets. Novo Nordisk struck two China-linked obesity deals after scrutiny of its next-wave pipeline: up to $2.6 billion for Jiangsu Hengrui’s HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP candidate, and $200 million upfront plus up to $1.8 billion more for United Laboratories’ UBT251, an experimental triple-agonist obesity shot. In both cases, Novo secured ex-China rights while the licensors kept mainland China, Hong Kong, Macao, and Taiwan rights.

Novartis also committed up to $7.8 billion in an mRNA partnership with Abogen that includes ABO2203 plus options on additional programs. Sanofi’s Henlius deal used milestones and royalties to secure target-specific oncology rights while pushing early execution risk outward. The common thread is a shift from single-asset buying to platform-led external innovation, where mechanism access, regional rights, and optionality matter as much as immediate market expansion. For operators and vendors, differentiated platforms, discovery access, and scalable CMC or manufacturing capacity are becoming the monetizable assets. For investors, value is moving toward companies that can repeatedly turn reusable science and infrastructure into deal leverage.

Diagnostics and AI Are Becoming the Precision Oncology Moat

Capital is shifting from single-asset oncology bets to a platform stack where diagnostics, AI analytics, and companion testing decide which therapies reach patients. That matters because the value is moving upstream: whoever controls patient selection increasingly controls trial efficiency, label expansion, and commercial access.

Recent financings show the pattern. Freenome raised $254 million in 2024 for a multi-omics platform spanning cfDNA, protein, and RNA. GeneCentric closed a Series C in June 2025 for liquid biopsy. Cofactor Genomics expanded OncoPrism with backing from Labcorp and Ascension Ventures. Precision Biologics announced a $50 million equity investment pairing tumor-specific antibodies with companion diagnostics, while Acurion raised $4.3 million for an AI-driven precision oncology platform. Tempus-linked work in ARPA-H’s ADAPT program extends the same logic into AI-driven biomarker and trial design.

For operators and investors, the competitive edge is no longer just in the drug asset. It is in owning the data layer that identifies the right patient, shortens development cycles, and captures a larger share of oncology value.